FindTrial
Sign In

A clinical trial to know the effects of LT4/LT3 combination therapy in improving the quality of life & to look for change in body mass index, body weight, lipid profile among adults patients with primary hypothyroidism.

Effects of LT4/LT3 combination therapy in improving the quality of life & metabolic parameters among adult patients with primary hypothyroidism- A Randomized controlled trial. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053860
Enrollment
60
Registered
2023-06-14
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E038- Other specified hypothyroidism

Interventions

Intervention1: Levothyroxine(LT4) and Liothyronine(LT3): Intervention group will receive both LT4 and LT3 combination therapy daily perorally for a duration of 24weeks. The dose of LT3 will be given i

Sponsors

DrBinod Prusty
Lead Sponsor
Dr Dayanidhi Meher
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All hypothyroid patients aged 18 to 60 years who had been diagnosed with primary hypothyroidism and were on a stable dose of LT4 with serum TSH being normal i.e,(0.35-4.2microIU/ml) for atleast 3months

Exclusion criteria

Exclusion criteria: 1)Pregnant women planning for pregnancy, vitamin D deficiency, any history of renal, hepatic or cardiac dysfunction, hypocortisolemia. 2)Drugs including psychotropic medications, rifampicin, phenytoin, oral contraceptives and study groups patients during any point of study if serum TSH not in normal range.

Design outcomes

Primary

MeasureTime frame
1. To assess the effectiveness of LT4/LT3 combination therapy in improving quality of life among adult primary hypothyroidism patients.Timepoint: Baseline 12 weeks 24 weeks—

Secondary

MeasureTime frame
1.Change in body weight. 2.Change in Body-mass index. 3.Change in fasting lipid profile. 4.Change in Serum TSH, Serum FT4, Serum FT3 , Serum T4, Serum T3. 5.Change in HbA1C . 6.Treatment preference. Timepoint: Baseline 12 weeks 24 weeks—

Countries

India

Contacts

Public ContactBinod Prusty

Kalinga Institute of Medical Sciences, Bhubaneswar,Odisha

dayanidhi.meher@gmail.com9937793342

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026